BioPharma Credit PLC Announcement
Date: July 15, 2026
Investment in Kestra Medical:
BioPharma Credit PLC is pleased to announce a new investment of up to US$45 million in Kestra Medical Technologies, Inc. This investment is part of a loan agreement in which BioPharma Credit, through its subsidiary, collaborates with BioPharma Credit Investments V (Master) LP.
Loan Agreement Summary:
- Total Investment: Up to US$45 million from BioPharma Credit and up to US$105 million from BioPharma-V.
- Funding Structure:
- Tranche A: US$22.5 million (funded at agreement signing).
- Tranche B: US$7.5 million (available until July 31, 2027).
- Tranche C: US$15 million (available until June 30, 2028).
- Uncommitted Tranche D: US$15 million (subject to mutual agreement).
Loan Details:
- Maturity: July 2031.
- Interest Rate: 3-month SOFR + 5.50% (3.25% SOFR floor).
- Additional Fees: A one-time consideration of 1.75% on each tranche, plus potential prepayment and exit fees.
About Kestra Medical:
Kestra is a commercial-stage wearable medical device company focused on improving cardiovascular outcomes. Its current market capitalization is approximately US$1.59 billion. Kestra’s primary product is the ASSURE System, designed to protect at-risk patients from sudden cardiac arrest, generating US$95 million in revenues for the fiscal year ending April 30, 2026.
For inquiries, contact:
BioPharma Credit PLC via MUFG Corporate Governance Limited:
- Company Secretary: +44 (0) 333 300 1932
Burson Buchanan Contacts:
- Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill: +44 (0)20 7466 5000
- Email: biopharmacredit@buchanan.uk.com
Company Information:
BioPharma Credit PLC, listed since March 2017, specializes in debt investments in the life sciences sector, focusing on long-term income from secured debt assets related to approved life sciences products.
This announcement is provided by RNS, the news service of the London Stock Exchange.
